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Simple Summary: Predicting the aggressiveness of solid pseudopapillary neoplasms (SPNs) re-
mains a worthwhile goal. The present study aimed to identify perioperative factors that can predict
patients who will develop clinically aggressive SPN. A total of 98 patients diagnosed with SPNs
were analyzed retrospectively. We found that age (≥40 years; p = 0.039), symptomatic presentation
(p = 0.001), tumor size (>10 cm; p < 0.001), positron emission tomography/computed tomography
(PET/CT) classification (Type III; p < 0.001), and lymphovascular invasion (p = 0.003) were signifi-
cantly correlated with aggressive behavior of SPNs. Among these, age ≥40 years, PET/CT Type III
configuration, and lymphovascular invasion were independent factors associated with an aggressive
SPN. This information can help clinicians develop individualized management and surveillance
plans to manage patients more competently.
Abstract: Predicting the aggressiveness of solid pseudopapillary neoplasms (SPNs) remains an
important goal. The present study aimed to identify perioperative factors that can predict patients
who will develop clinically aggressive SPN. Records of individuals with pathologically confirmed
SPN from 2006 to 2017 were obtained from the patient registry database of Yonsei University,
Severance Hospital. For this study, aggressive behavior was defined as SPN that had recurred,
metastasized, or involved adjacent organs. A total of 98 patients diagnosed with SPNs were analyzed
retrospectively. Of these, 10 were reported to have SPNs with aggressive characteristics. We found
that age (≥40 years; p = 0.039), symptomatic presentation (p = 0.001), tumor size (>10 cm; p < 0.001),
positron emission tomography/computed tomography (PET/CT) classification (p < 0.001), and
lymphovascular invasion (p = 0.003) were significantly correlated with aggressive behavior of SPNs.
Multivariate analysis showed that PET/CT configuration (p = 0.002) (exp(β)111.353 (95% confidence
interval (CI): 5.960–2081), age ≥40 years (p = 0.015) (exp(β) 23.242 (95% CI: 1.854–291.4)), and
lymphovascular invasion (p = 0.021) (exp(β) 22.511 (95% CI: 1.595–317.6)) were the only independent
factors associated with aggressive SPN. Our data suggest that age ≥40 years, PET/CT Type III
configuration, and lymphovascular invasion are independent factors associated with aggressive SPN.
This information can help clinicians develop individualized management and surveillance plans to
manage patients more effectively.
Keywords: aggressive tumor; pancreas; pancreatic neoplasm; solid pseudopapillary tumor; aggres-
sive pancreatic cancer
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1. Introduction
Solid pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant
neoplasm that accounts for only 1–2% of all pancreatic neoplasms [1–4]. SPN of the
pancreas is usually non-aggressive, but up to 10–15% of neoplasms have been reported
to be aggressive [5]. Describing and characterizing the natural course of SPNs has been
difficult owing to the rarity of this disease, as well as the inconsistent correlation between
the pathological characteristics and clinical course.
Several studies have attempted to identify factors that could predict the aggressive
behavior of SPNs, including age [6], sex [7], neutrophil-to-lymphocyte ratio [8], tumor
size [5,9–11], resection margin [6], Ki-67 index [1,12–14], pathological variables, such as
lymphovascular and perineural invasion [1,12,15], and radiologic findings on magnetic
resonance imaging (MRI) and positron emission tomography/computed tomography
(PET/CT) [16–21]. Meanwhile, several other studies have reported that there are no
clinicopathologic factors that can predict tumor behavior [22–26].
Predicting the aggressiveness of SPNs remains a worthwhile goal. Identifying patients
with aggressive SPNs can help surgeons create individualized clinical management and
surveillance strategies [27,28]. This study aimed to identify perioperative factors that can
predict patients who will develop clinically aggressive SPN.
2. Materials and Methods
2.1. Definition of Terms
In this study, aggressive behavior was defined as SPN that either locally invaded
adjacent structures, developed recurrence, or had systemic metastasis, whether at initial
diagnosis or at a later course.
2.2. Data Collection
Patient records from 2006 to 2017 mentioning SPN were obtained from the patient reg-
istry database of Yonsei University Severance Hospital. These records were then reviewed
in search of a pathologically confirmed diagnosis of SPN of the pancreas. Perioperative
data, including age, sex, body mass index, symptoms at presentation, operation date, and
type of operation were collected and encoded into a spreadsheet. Preoperative ancillary
data, such as imaging studies and PET/CT scan results, were also included, specifically,
the fluorodeoxyglucose (FDG) uptake pattern on PET/CT, as described by Kang et al. [17].
There are five types of PET/CT uptake classifications: Type I (hot FDG uptake in the entire
tumor portion), Type II (focal defect), Type III (multiple and geographic uptake), Type
IV (focal uptake), and Type V (total defective type). Postoperative results, such as the
complication rate, length of hospital stay, and pathologic reports, were also tabulated into
the spreadsheet. All cases were reviewed by immunohistochemical staining, including
beta-catenin and Ki-67. Patients who had undergone definitive disease-related surgeries at
other institutions, as well as those who had a preoperative diagnosis of SPN but were yet
to undergo definitive surgery, were excluded from this study.
2.3. Statistical Analysis of Baseline Characteristics
International Business Machines Corporation SPSS Statistics Version 23 (SPSS, Inc.,
Chicago, IL, USA) was used for all statistical analyses. Continuous variables are represented
as the means ± standard deviations or medians with ranges, while categorical variables
are represented as percentages or frequencies. Continuous variables were compared using
Student’s t-test, while categorical variables were compared using Fisher’s exact test or
the chi-squared test. A binary logistic regression analysis was used to determine whether
the factors affecting aggressive behavior were independent of each other. A statistically
meaningful value for predicting aggressive behavior was set as the cutoff value. Statistical
significance was set at p < 0.05.
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3. Results
3.1. General Patient Data
From 2006 to 2017, 98 patients had pathologically confirmed pancreatic SPN. The
female to male ratio was 83:15 (or 5.53:1), and the average age of the participants was
36.03 years. Table 1 shows a summary of patient information.
Table 1. General patient data of all 98 patients.
Variables No. of Patients (%)
Age 36.03 ± 15.6
Sex (F/M) 83 (84.7%)/15 (15.3%)
BMI 22.05 ± 3.3
Symptomatic (yes/no) 42 (42.9%)/56 (57.1%)
Abdominal pain 35 (83.3%)
Abdominal mass 9 (29.4%)
Tumor size (cm) 4.6 ± 2.8
Tumor location (proximal/distal) 29 (29.6%)/69 (70.4%)
Operation type (minimally invasive/open) 64 (65.3%)/34 (34.7%)
Operation -
PPPD 21 (21.4%)
Central pancreatectomy 9 (9.2%)
Distal pancreatectomy 62 (63.3%)
Enucleation 5 (5.1%)
Biopsy 1 (1.0%)
Values are n (%), mean ± standard deviation. BMI, body mass index; PPPD, pylorus-preserving pancreaticoduo-
denectomy.
3.2. Preoperative Evaluation
All patients underwent preoperative imaging (CT or MRI) to determine the neoplasm
characteristics. However, only 86 patients (87.8%) underwent PET/CT. Table 2 summarizes
the preoperative PET/CT findings.
Table 2. Clinical pattern of preoperative PET/CT in all 86 patients.
PET/CT Scan Uptake
Classification 1 Scheme Description No. of Patients (%) Representative PET/CT Image
Type I
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Table 3. Surgical outcomes of all 98 patients.
Variables No. of Patients (%)
Disease-specific deaths 6 (6.1%)
R0 resection 98 (100%)
Positive margins 0 (0%)
Microscopic pathology -
Capsular invasion 24 (24.5%)
Lymphovascular invasion 35 (83.3%)
Perineural invasion 9 (29.4%)
Ki-67 4.6 ± 2.8
Complication 1 29 (29.6%)
Clavien–Dindo Class I 2 (2%)
Clavien–Dindo Class II 15 (15.3%)
Clavien–Dindo Class IIIa/IIIb 7 (7.1%)/3 (3.1%)
Clavien–Dindo Class IV/V 1 (1%)/1 (1%)
Values are n (%), mean ± standard deviation. 1 Complication was graded according to the
Clavien–Dindo classification system [29].
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3.4. Patients with Aggressive Neoplasm
Ten patients (seven women, three men) had aggressive SPN; of these, six had systemic
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3.5. Factors Affecting Aggressive Behavior
We found that age (≥40 years; p = 0.039), symptomatic presentation (p = 0.001), tumor
size (>10 cm; p < 0.001), PET/CT classification (Type III; p < 0.001), and lymphovascu-
lar invasion (p = 0.003) were significantly correlated with aggressive behavior of SPNs.
Meanwhile, sex, tumor location, presence of complications, capsular invasion, perineural
invasion, and Ki-67 index were found to have no statistically significant correlation with
aggressive behavior of SPN. Table 5 summarizes the results of the statistical analyses.
Multivariate analysis showed that Type III PET/CT configuration (p = 0.002), age ≥40 years
(p = 0.015), and lymphovascular invasion (p = 0.021) were the only independent factors
associated with aggressive SPN. As independent factors with a 96.5% successful predictive
value for aggressiveness, Type III PET/CT configuration had an exp(β) of 111.353 (95%
confidence intervals (CI): 5.960 and 2081), while age ≥40 years and lymphovascular inva-
sion had exp(β) of 23.242 (95% CI: 1.854 and 291.4) and exp(β) of 22.511 (95% CI: 1.595 and
317.6), respectively.
Table 5. Characteristics of patients with aggressive and non-aggressive solid pseudopapillary tumor.
Variables Aggressive(n = 10)
Non-Aggressive
(n = 88) p-Value
p-Value
Exp(β) (95% CI)
Age - - - -




19–39 1 (10%) 43 (48.9%) 0.431 -
≤18 2 (20%) 13 (14.8%) 0.664 -
Sex (F/M) 7/3 76/12 0.173 -
BMI 21.7 ± 4.74 22.1 ± 3.10 0.804 -
Symptomatic (yes/no) 9/1 33/55 0.001 -
Location (proximal/distal) 4/6 25/63 0.447 -
Tumor size - - - -
≥10 cm 4 (40%) 2 (2.3%) <0.001 -
≥5 cm 6 (60%) 26 (29.5%) 0.052 -
≥2 cm 9 (90%) 71 (80.7%) 0.471 -




Type III 7 (77.8%) 16 (20.8%) - -
Non-Type III 2 (22.2%) 61 (79.2%) - -
Complication (yes/no) 4/6 26/62 0.497 -
Microscopic pathology - - - -
Margin All negative All negative - -
Capsular invasion 2 (20%) 16 (18.2%) 0.888 -




Perineural invasion 3 (30%) 11 (12.5%) 0.134 -
Ki-67 3.42 ± 4.52 2.10 ± 2.52 0.266 -
Values are n (%), mean ± standard deviation; PET, positron emission tomography; BMI,
body mass index; WBC, white blood cell; CI, confidence interval. * Independent variables
for predicting the aggressiveness of SPNs.
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4. Discussion
Advanced age, specifically ≥40 years, was an independent variable in predicting
the aggressiveness of SPNs. Aging is associated with numerous physiological changes
and adverse medical events. Advanced age amplifies the impact of certain conditions,
such as hypertension, diabetes, and certain tumors. Some studies have suggested that
cellular/physical degeneration and immune-related deterioration can be the cause of
age-related disease conditions [30–32].
PET/CT uses the enhanced glucose metabolism of cancer cells as a basis for differential
weighing and eventual detection of cancer cells [17,19,20]. An inherent characteristic of
neoplasms is that they replicate at an unregulated rate, presumably at a rate faster than
normal cells. We investigated the potential correlation between the clinical pattern of
preoperative PET/CT and the biological behavior of resected SPN of the pancreas [17,33].
Notably, we presented neoplasms with varying uptake patterns, while having a relatively
low Ki-67 index. The SPNs in our study presented all five types of uptake patterns, with an
almost equal distribution between types I and IV (27.9%, 20.9%, 26.7%, and 20.9%), and
Type V was the least frequent (3.5%). We also report that the Type III uptake pattern is an
independent factor in predicting aggressive type SPN. The reason for this remains unclear,
and requires further study. We recognize that other measurable parameters, such as the
mean and maximum standard uptake values, metabolic tumor volume, and total lesion
glycolysis, can provide information for the quantitative evaluation of neoplasms and their
aggressiveness [19].
While neoplasm growth varies significantly, that is, some neoplasms grow faster
than others, tumor size has always been associated with time. In general, the longer the
neoplasm is left undetected, the larger it can potentially become. De Robertis et al. reported
that large SPNs were more frequently located in the pancreatic body or tail (≥51 mm tumor
location: head (17.6%), body (32.4%), tail (47.4%), p = 0.008) [34]. This study explained
that this result is associated with a delayed diagnosis compared to that of pancreatic head
tumors because of the potential for maximal tumor growth without symptoms of premature
closure, such as jaundice and duodenal obstruction [34]. Thus, as the neoplasm enlarges,
it can potentially affect adjacent structures, as well as metastasize to distant organs, as
in the case of malignant lesions. This may rationalize our finding that the presence of
lymphovascular invasion, often seen in large (≥10 cm) neoplasms, is a factor related to
poor patient outcomes.
Similar to our findings, in a multicenter analysis in Korea, large tumors (>8 cm) were
reported to be predictive of recurrence (exp(β) = 7.385, p = 0.018) [10]. Several studies have
reported the importance of PET/CT as a predictor of aggressive behavior in SPNs [19,20].
Aisheng et al. reported that CT or MRI demonstrated morphological features of SPN,
and FDG PET/CT reflected the histopathological composition of the tumors [20]. They
explained that FDG uptake by SPN may be related to tumor cellularity, proliferative index,
or histological malignancy [20].
Contrary to our results, some studies reported that young age and male sex were
associated with SPN recurrence [6,7]. Sabine et al. reported that younger children had
a high risk of recurrence (p = 0.03) [6]. Matthew et al. reported that male patients have
an atypically aggressive biology of SPN [7]. Males had approximately twice the rates of
metastases and invasive malignancy, and a threefold higher death rate than that of females
(p = 0.036, p = 0.003, p = 0.002, respectively) [7]. In our study, there was no difference in
the incidence of aggressive SPN in younger individuals under 18 years of age (p = 0.664),
and aggressive SPN was identified as a risk factor for individuals who were 40 years of
age or older (exp(β) = 23.242, p = 0.015). In addition, there was no statistically significant
difference between males and females for aggressive SPN (p = 0.173).
Studies have shown that SPNs of the pancreas occur because of a somatic point
mutation in exon 3 of CTNNB1, which encodes the β-catenin pathway [12,35]. This
distinguishes it from other known pancreatic neoplasms. Meng et al. conducted whole
exome sequencing in nine patients with SPN, and found that the CTNNB1 mutation
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potently collaborated with other gene variations [36]. Shmuel et al. reported that a panel
of six miRNAs, including miR-184, miR-10a, miR-887, miR-217, miR200c, and miR-375,
were significantly expressed in metastatic SPNs. These specific miRNAs have potential as
predictive markers of aggressive behavior of SPN [37]. However, despite our knowledge
of its genetic basis, the natural and clinical course of the disease remains unclear.
The results of this study presented clinical predictors, including PET/CT, to provide
the basis for implementing PET/CT when treating patients with SPN in clinical practice.
In patients with symptoms at diagnosis, large tumors (≥10 cm), and old age (≥40 years),
PET/CT can be performed to check for aggressive behavior. The Type III uptake pat-
tern of PET/CT can be considered as an indicator for active surgery and postoperative
chemotherapy. To the contrary, patients with Type IV and V, mostly containing a defec-
tive background with minimal or null FDG uptake, could be carefully followed without
surgery according to the patient’s individual conditions, such as co-morbidity, refusal of
surgery, and active personal schedule [33]. These SPNs may show very indolent biological
behavior or total necrosis [33]. Therefore, the results of this study are expected to help SPN
treatment decisions.
This study has limitations related to its retrospective design and the small size of data.
Moreover, there was a selection bias, since we only analyzed patients who underwent
surgery. We recommend further studies on the potential of qualitative parameters in
PET/CT scans as predictive factors for aggressiveness. We also recommend further research
into the clinical course of SPN, along with its immunohistochemical and preoperative
laboratory profiles, as well as the molecular basis of perilesional inflammation, to fully
understand the pathophysiology of this neoplasm.
5. Conclusions
In conclusion, our data suggest that, in patients with SPN, age ≥40 years, symptomatic
at presentation, tumor size ≥10 cm, and PET/CT scan configuration Type III are all predic-
tive of aggressive neoplasm behavior. Lymphovascular invasion of the neoplasm, as seen
in the pathological report, can also be a valuable predictor. Among these, age ≥ 40 years,
PET/CT Type III configuration, and lymphovascular invasion are independent factors asso-
ciated with an aggressive SPN. This information can help clinicians develop individualized
management and surveillance plans to manage patients more competently.
Complete surgical resection remains the standard management for SPNs, but diligent
surveillance may be warranted to detect recurrence or metastasis.
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